Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 8/20 | 1.00 |
| ▸ | CCNH | P51946 | 8/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 5/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 2/20 | 0.84 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.84 |
| ▸ | PAK4 | O96013 | 12/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741190 | 1.00 | CDK7 (1.00) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL18313535 | 0.95 | CDK7 (0.91) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20741117 | 0.95 | CDK7 (0.91) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17878808 | 0.94 | CDK7 (0.89) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17872121 | 0.94 | CDK7 (0.89) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20741166 | 0.92 | CDK7 (0.85) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17878659 | 0.92 | CDK7 (0.85) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL20741187 | 0.92 | CDK7 (0.93) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17878765 | 0.92 | CDK7 (0.93) | CDK7CCNHMNAT1CDK2CCNT1 | |
| SCHEMBL17872131 | 0.92 | CDK7 (1.00) | CDK7CCNHMNAT1CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | claimed |
| US-20240240208-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF PRECISE EDITING REPAIR | NEW YORK GENOME CENTER INC (US) | 2024-07-18 | — | — | US | claimed |
| EP-4347815-A2 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF PRECISE EDITING REPAIR | New York Genome Center, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117715678-A | Electrode assembly for applying a Tumor Treatment Field (TTFIELD) using an anisotropic sheet of material | 诺沃库勒有限责任公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | MEDIC LIFE SCIENCES, INC. | 2023-07-06 | — | — | US | claimed |
| EP-4157465-A2 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | Syros Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2023012707-A1 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL | NOVOCURE GMBH (CH) | 2023-02-09 | — | — | WO | claimed |
| EP-4126014-A1 | COMBINATION THERAPEUTICS USING TUMOR TREATING FIELDS (TTFIELDS) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-08 | — | — | EP | claimed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | claimed |
| WO-2022251836-A2 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF PRECISE EDITING REPAIR | NEW YORK GENOME CENTER, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| CN-115379854-A | Combination therapy with Tumor Therapy Field (TTFIELD) | 得克萨斯大学体系董事会 | 2022-11-22 | — | — | CN | claimed |
| EP-4051282-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| CN-114901284-A | Methods of treating cancer in patients identified by biomarkers with cyclin dependent kinase 7(CDK7) inhibitors | 希洛斯医药品股份有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | CDKL5, KRAS, CDK9 | CDK7 12/4885CCNH 255/4885MNAT1 2693/4885 |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, RB1, MKI67 | CDK7 1/4885CCNH 17/4885MNAT1 1007/4885 |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | CDK9, CDC73, CDK4 | CDK7 10/4885CCNH 185/4885MNAT1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.